These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children. Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Swidan SZ; Lake AE; Saper JR Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028 [TBL] [Abstract][Full Text] [Related]
6. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Klapper JA; Stanton JS Headache; 1991 Sep; 31(8):523-4. PubMed ID: 1960056 [TBL] [Abstract][Full Text] [Related]
7. Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review. Srouji R; Schenkel SR; Forbes P; Cahill JE Headache; 2021 May; 61(5):777-789. PubMed ID: 34105158 [TBL] [Abstract][Full Text] [Related]
8. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Ford RG; Ford KT Headache; 1997 Mar; 37(3):129-36. PubMed ID: 9100396 [TBL] [Abstract][Full Text] [Related]
9. Repetitive intravenous DHE in the treatment of refractory headache. Silberstein SD; Schulman EA; Hopkins MM Headache; 1990 May; 30(6):334-9. PubMed ID: 2370132 [TBL] [Abstract][Full Text] [Related]
11. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Robbins NM; Ito H; Scheinman MM; Goadsby PJ Neurology; 2016 Dec; 87(24):2522-2526. PubMed ID: 27837002 [TBL] [Abstract][Full Text] [Related]
12. Use of dihydroergotamine in patients with postconcussion syndrome. McBeath JG; Nanda A Headache; 1994 Mar; 34(3):148-51. PubMed ID: 8200788 [TBL] [Abstract][Full Text] [Related]
13. Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP"). Connelly M; Sekhon S; Stephens D; Boorigie M; Bickel J Headache; 2020 Jan; 60(1):101-109. PubMed ID: 31626335 [TBL] [Abstract][Full Text] [Related]
15. Dihydroergotamine and metoclopramide in the treatment of organic headache. Gross DW; Donat JR; Boyle CA Headache; 1995; 35(10):637-8. PubMed ID: 8550366 [TBL] [Abstract][Full Text] [Related]
16. Outcome and Cost of Inpatient Hospitalization for Intravenous Dihydroergotamine Treatment of Refractory Pediatric Headache. Nelson GR; Bale JF; Kerr LM Pediatr Neurol; 2017 Jan; 66():76-81. PubMed ID: 27847180 [TBL] [Abstract][Full Text] [Related]
17. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Fisher M; Gosy EJ; Heary B; Shaw D Curr Med Res Opin; 2007 Apr; 23(4):751-5. PubMed ID: 17407631 [TBL] [Abstract][Full Text] [Related]
18. In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Pringsheim T; Howse D Can J Neurol Sci; 1998 May; 25(2):146-50. PubMed ID: 9604137 [TBL] [Abstract][Full Text] [Related]
19. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Belgrade MJ; Ling LJ; Schleevogt MB; Ettinger MG; Ruiz E Neurology; 1989 Apr; 39(4):590-2. PubMed ID: 2648190 [TBL] [Abstract][Full Text] [Related]
20. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? Morren JA; Galvez-Jimenez N Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]